In an initial clinical trial where an anti-CTLA-4 blocking antibody was administered to patients with metastatic melanoma in combination with peptide vaccines containing melanoma-associated antigens, 43% of patients (6 out of 14) experienced grade III/IV autoimmunity affecting multiple organs (12). Here, CTLA4 is linked to melanoma.